Is there an increased risk of spinal relapse in standard-risk medulloblastoma/primitive neuroectodermal tumor patients who receive only a reduced dose of craniospinal radiotherapy?
Medulloblastoma (MBL) is the most common pediatric brain malignancy. Postoperative radiotherapy to the entire craniospinal axis is the standard-of-care but has linked to long-term morbidity. In this study, we analyzed the implication of reduced dose craniospinal radiotherapy (RT) for survival and pattern of relapse in MBL patients.
Material and methods
The clinical characteristics of 32 consecutively diagnosed medulloblastoma/primitive neuroectodermal tumor patients were analyzed. After surgical resection, a dose of 23.4 Gy of spinal RT with a posterior fossa boost of 30.6 Gy was prescribed to standard-risk patients, whereas high-risk patients received 36 Gy spinal RT with additional boosts to the posterior fossa up to 54 Gy. Then, both groups received the same chemotherapy protocol.
Five-year OS for standard and high-risk patients was 94 and 50%, respectively. When analyzing prognostic factors, postoperative tumor size is the most important one which affects the OS. Ten patients relapsed during follow-up, and there was no isolated spinal relapse in either group.
The risk of isolated spinal relapse does not increase with reduced-dose craniospinal RT, since there is no isolated relapse in either the standard or high-risk groups of patients.
KeywordsMedulloblastoma Primitive neuroectodermal tumor Spinal relapse Radiotherapy
Compliance with ethical standards
Conflict of interest
The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.
- 7.Geyer RJ, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, Broxson E, Donahue B, Finlay JL, Goldwein JW et al (2005) Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J Clin Oncol 23:7621–7631CrossRefPubMedGoogle Scholar
- 9.Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, Von Dcimlig A, Aldapc K, Brat D, Collins VP, Eberhant C et al (2014) International Society of Neuropathology- Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24:429–435CrossRefPubMedGoogle Scholar
- 15.Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-Oncology 16(4):1–63. https://doi.org/10.1093/neuonch/nou223 CrossRefGoogle Scholar
- 21.Packer RJ, Gajjar A, Vazina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Maryment MH et al (2006) Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average–risk medulloblastoma. J Clin Oncol 24:4202–4208CrossRefPubMedGoogle Scholar
- 24.Parkes J, Hendricks M, Ssenyoga P, Mugamba J, Molyneux E, Schouten-van Meeteren A, Qaddoumi I, Fieggen G, Luna-Firemen S, Howard S et al (2015) SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low and middle income settings. Pediatr Blood Cancer 62:553–564CrossRefPubMedGoogle Scholar
- 28.Rutkauskiene G, Labanauskas L, Jarusevicius L (2006) The results of the treatment of childhood medulloblastoma with radiotherapy at Kaunas University of Medicine Hospital in 1994–2000. Medicana(Kaunas) 42(1):22–32Google Scholar
- 33.Zeltster PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, Allen JC, Stevens KR, Stanley P, Li H et al (1999) Metastasis stage, adjuvant treatment and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 17(2):832–845CrossRefGoogle Scholar